Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men

Diabetes, Obesity and Metabolism

Volumn 18, Issue 2, 2016, Pages 178-185

  Muskiet, M H A ^a   Tonneijck, L ^a   Smits, M M ^a   Kramer, M H H ^a   Diamant, M ^a   Joles, J A ^b   van Raalte, D H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Exenatide; GLP 1 receptor agonist; L NMMA; Nitric oxide; Renal haemodynamics

Indexed keywords

4 AMINOHIPPURIC ACID; ELECTROLYTE; EXENDIN 4; INULIN; N(G) METHYLARGININE; NITRIC OXIDE; PLACEBO; ANTIDIABETIC AGENT; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NITRIC OXIDE SYNTHASE; PEPTIDE; VENOM;

ACUTE RENAL HEMODYNAMIC EFFECT; ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROLYTE URINE LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; HYDROSTATIC PRESSURE; INULIN CLEARANCE; KIDNEY ARTERY; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY TUBULE FUNCTION; MALE; NORMAL HUMAN; OBESITY; URINE OSMOLALITY; URINE PH; VASCULAR RESISTANCE; AGONISTS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CIRCULATION; KIDNEY TUBULE; METABOLIC CLEARANCE RATE; METABOLISM; PATHOPHYSIOLOGY; URINE; VASCULARIZATION; YOUNG ADULT;

ADULT; BODY MASS INDEX; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY TUBULES; MALE; METABOLIC CLEARANCE RATE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; OVERWEIGHT; PEPTIDES; RENAL CIRCULATION; VASCULAR RESISTANCE; VENOMS; YOUNG ADULT;

EID: 84957063828     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12601     Document Type: Article

References (36)

1. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-442.
2. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10: 88-103.
3. Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013; 4: 190-201.
4. Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Heerspink HJ, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 2015; 3: 367-381.
5. Pfeffer MA. The evaluation of lixisenatide in acute coronary syndrome - the results of ELIXA. Session 3-CT-SY28. Oral presentation at the American Diabetes Association 2015 Scientific Sessions, Boston, MA, June 8th, 2015.
6. Gutzwiller JP, Tschopp S, Bock A etal. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-3061.
7. Crajoinas RO, Oricchio FT, Pessoa TD etal. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301: F355-F363.
8. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002; 434: 163-167.
9. Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 2013; 304: F137-F144.
10. Jensen EP, Poulsen SS, Kissow H etal. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Renal Physiol 2015; 308: F867-F877.
11. Skov J, Dejgaard A, Frøkiær J etal. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98: E664-E671.
12. Asmar A, Simonsen L, Asmar M etal. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 2015; 308: E641-E649.
13. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009; 157: 8-13.
14. Idris I, Patiag D, Gray S, Donnelly R. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 2002; 63: 993-996.
15. Smits MM, Muskiet MH, Tonneijck L etal. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol 2015; 35: 1538-1543.
16. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
17. Gomez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 1951; 30: 1143-1155.
18. Fehse F, Trautmann M, Holst JJ etal. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
19. Ide K, Worthley M, Anderson T, Poulin MJ. Effects of the nitric oxide synthase inhibitor L-NMMA on cerebrovascular and cardiovascular responses to hypoxia and hypercapnia in humans. J Physiol 2007; 584: 321-332.
20. Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta; 1956; 1: 470-474.
21. Waugh WH, Beall PT. Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 1974; 5: 429-436.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
23. Delles C, Klingbeil AU, Schneider MP, Handrock R, Schäufele T, Schmieder RE. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant 2004; 19: 1392-1397.
24. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
25. Von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 2015; 32: 343-352.
26. Pyke C, Heller RS, Kirk RK etal. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-1290.
27. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014; 114: 1788-1803.
28. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173-177.
29. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008; 478: 136-142.
30. Tsuda A, Ishimura E, Ohno Y etal. Significant association of poor glycemic control with increased resistance in efferent arterioles-study of inulin and para-aminohippuric acid clearance in humans. Diabetes Res Clin Pract 2014; 104: 234-240.
31. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132-139.
32. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012; 74: 437-444.
33. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
34. Cherney DZ, Perkins BA, Soleymanlou N etal. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
35. Skrtić M, Yang GK, Perkins BA etal. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57: 2599-2602.
36. Tonneijck L, Smits MM, van Raalte DH, Muskiet MH. Incretin-based drugs and renoprotection-is hyperfiltration key? Kidney Int 2015; 87: 660-661.